SQZ Biotechnologies to Present at Upcoming Health Care Conferences - Sep 09, 2021

Sept. 9, 2021 10:45 UTC

WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at Citi’s 16th Annual Virtual Biopharma Conference on September 10, and at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13.

Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings at both conferences.


Friday, September 10
Citi’s 16th Annual Virtual Biopharma Conference
Corporate Overview
12:30-1:15 pm EDT

Monday, September 13
H. C. Wainwright 23rd Annual Global Investment Conference
Corporate Overview (pre-recorded)
7:00-7:20 am EDT

Specific conference webcast details and the company’s corporate overview presentation will be available on the Investors & Media section of the SQZ website. The webcasts will be available for 90 days following the presentation.

About SQZ Biotechnologies
SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases. For more information, please visit www.sqzbiotech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005242/en/


SQZ Biotechnologies Investor Relations:

SQZ Biotechnologies Media Contact:
John Lacey
Corporate Communications

Source: SQZ Biotechnologies

Back to news